Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Autologous TIL 13831 TCR transduced T cells|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Autologous TIL 13831 TCR transduced T cells||Autologous TIL 13831 TCR transduced T cells are T-cells isolated from a patient and engineered to express a T-cell receptor (TCR) that targets an MHC class I-restricted tyrosinase peptide, potentially resulting in increased immune response against tyrosinase-expressing tumors (PMID: 20624956).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT02870244||Phase I||Autologous TIL 13831 TCR transduced T cells||Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes||Recruiting|